KRON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kronos Bio's Enterprise Value is $-84.63 Mil. Kronos Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-121.83 Mil. Therefore, Kronos Bio's EV-to-EBIT ratio for today is 0.69.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kronos Bio's Enterprise Value is $-84.63 Mil. Kronos Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-119.69 Mil. Therefore, Kronos Bio's EV-to-EBITDA ratio for today is 0.71.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kronos Bio's Enterprise Value is $-84.63 Mil. Kronos Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $6.29 Mil. Therefore, Kronos Bio's EV-to-Revenue ratio for today is -13.46.
The historical data trend for Kronos Bio's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Enterprise Value | Get a 7-Day Free Trial | - | 1,234.19 | 451.26 | -114.81 | -71.04 |
Kronos Bio Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | -114.81 | -111.69 | -89.33 | -81.54 | -71.04 |
For the Biotechnology subindustry, Kronos Bio's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kronos Bio's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Kronos Bio's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Kronos Bio's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 73.6825 | + | 0 | + | 25.379 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.893 | + | 0 | - | 172.997 |
= | -71.04 |
Kronos Bio's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 73.6825 | + | 0 | + | 25.379 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.893 | + | 0 | - | 172.997 |
= | -71.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio (NAS:KRON) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Kronos Bio's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -84.630 | / | -121.83 | |
= | 0.69 |
Kronos Bio's current Enterprise Value is $-84.63 Mil.
Kronos Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-121.83 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Kronos Bio's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | -84.630 | / | -119.694 | |
= | 0.71 |
Kronos Bio's current Enterprise Value is $-84.63 Mil.
Kronos Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.69 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Kronos Bio's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -84.630 | / | 6.288 | |
= | -13.46 |
Kronos Bio's current Enterprise Value is $-84.63 Mil.
Kronos Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Kronos Bio's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Jorge Dimartino | officer: Chief Medical Officer & VP | C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402 |
Christopher Dinsmore | officer: Chief Scientific Officer | C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402 |
Barbara Kosacz | officer: COO & General Counsel | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Norbert W Bischofberger | director, 10 percent owner, officer: President & CEO | 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404 |
Sandra A. Gardiner | officer: Interim CFO | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Yasir B. Al-wakeel | officer: Chief Financial Officer | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Roger D Dansey | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Katherine V Stultz | director | C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
Backer Marianne De | director | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Jakob Loven | director | C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511 |
Taiyin Yang | director | 2631 HANOVER STREET, PALO ALTO CA 94304 |
Otello Stampacchia | director, 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
John C Martin | director | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Elena Ridloff | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-30-2022
By PurpleRose PurpleRose • 07-11-2022
By Value_Insider Value_Insider • 11-08-2022
By PurpleRose PurpleRose • 08-16-2022
By GlobeNewswire GlobeNewswire • 12-11-2022
By sperokesalga sperokesalga • 06-01-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By sperokesalga sperokesalga • 02-28-2023
By PurpleRose PurpleRose • 08-22-2022
By Value_Insider Value_Insider • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.